跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 144 条关于
“Hypophosphatasia”
全部
144
临床试验
121
药物
4
机构
0
资讯
19
去年
Alexion Partners with Pangaea Data to Develop AI System for Hypophosphatasia Detection
上个月
BioMarin acquires Alesta Therapeutics and its hypophosphatasia drug ALE1 in $275M deal
3个月前
Hypophosphatasia Market Poised for Robust Growth Through 2036 as Next-Generation Therapies Advance
5个月前
AstraZeneca's Efzimfotase Alfa Shows Promise in Phase III Hypophosphatasia Trials with Mixed Results
去年
Be Biopharma to Present Promising Nonclinical Data for Novel B Cell Therapy in Hypophosphatasia Treatment
上个月
BioMarin to Acquire Alesta Therapeutics for ALE1, a Potential First Oral Therapy for Hypophosphatasia
去年
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
去年
Be Bio Secures $92 Million to Advance B Cell Medicines for Hemophilia B and Hypophosphatasia
昨天
FDA Grants Priority Review to Alexion's Efzimfotase Alfa BLA for Hypophosphatasia
去年
Rallybio Advances FNAIT Candidate RLYB212 to Phase 2 Trial, Eyes Expanded Market
第 1 页,共 2 页
上一页
下一页